Medical Cannabis for Spinal Cord Injuries UK

Understanding Spinal Cord Injury and Spasticity
Spinal cord injury (SCI) affects approximately 1,000 people annually in the UK. One of the most debilitating consequences is spasticity, affecting up to 65-78% of SCI patients. Spasticity involves involuntary muscle contractions and increased muscle tone, which can severely impact mobility, pain levels, and quality of life. Traditional treatments including physiotherapy, oral medications such as baclofen and tizanidine, and botulinum toxin injections often provide insufficient relief, leaving many patients searching for alternative therapies.

Sativex: Evidence from Multiple Sclerosis to SCI
Sativex (nabiximols) is currently the only cannabis-based medicine approved by the National Institute for Health and Care Excellence (NICE) in the UK, though primarily licensed for multiple sclerosis spasticity. This oromucosal spray contains equal amounts of THC and CBD (approximately 1:1 ratio), delivering 100 micrograms of each cannabinoid per spray. The approval for MS spasticity is significant for SCI patients because the underlying neurophysiology producing spasticity shares considerable similarities between these conditions. Clinical trials demonstrate Sativex’s efficacy in reducing muscle tone and pain associated with spasticity, making it a logical consideration for SCI-related symptoms.

Clinical Evidence for Cannabis in SCI Spasticity

Research specifically examining cannabis use in SCI patients reveals promising results. Multiple studies indicate that cannabinoids effectively reduce spasticity severity, with many patients reporting improved sleep quality and reduced associated pain. A key advantage of cannabis over conventional medications is the favourable side effect profile compared to high-dose baclofen, which commonly causes sedation and weakness. The mechanism appears to involve cannabinoid receptor activation in spinal cord circuits responsible for motor control. Additionally, evidence supports cannabis’s efficacy for neuropathic pain, an extremely common complication following SCI affecting approximately 40-50% of patients. Unlike opioids, cannabinoids carry minimal addiction potential and do not cause respiratory depression.

Obtaining a UK Prescription for SCI

Since November 2018, specialist doctors in the UK can legally prescribe cannabis-based medicinal products. However, accessing treatment requires navigating specific criteria. Patients must demonstrate that conventional treatments have proven ineffective or intolerable. Specialist centres, particularly those specialising in neurology, spasticity management, or pain medicine, are most likely to consider cannabis prescriptions. Many NHS specialists remain cautious, though private specialists increasingly offer consultations. Patients should prepare comprehensive documentation of previous treatments attempted and their outcomes. The process typically involves assessment by a consultant, possibly including functional assessments of spasticity using standard scales such as the Modified Ashworth Scale.

Optimal Products for SCI Spasticity Management

For spasticity specifically, balanced THC:CBD products similar to Sativex’s 1:1 ratio appear most effective based on clinical evidence. This balance provides spasticity-reducing benefits whilst minimising intoxication that high-THC products might cause. Products should offer titrateable dosing, allowing patients to find their minimum effective dose. Oromucosal sprays provide advantages for wheelchair users, requiring no additional equipment or preparation. Alternatively, oral solutions and capsules offer convenience for patients with limited dexterity or hand function.

Practical Considerations for SCI Patients

SCI patients considering cannabis should discuss potential interactions with existing medications, particularly muscle relaxants and pain medications. Starting with low doses and gradual titration minimises adverse effects. Regular monitoring by healthcare providers ensures continued efficacy and appropriate dosing adjustments. Many patients benefit from consistent timing of doses, ideally before physiotherapy sessions for improved participation.

Wheelchair User-Specific Considerations

Wheelchair users require particular attention to medication delivery methods. Oromucosal sprays avoid requirements for hand dexterity that smoking or vaping might demand. Patients should store medications securely and accessibly, considering limited reach in wheelchair positions. Some users report improved transfer independence and reduced muscle tension with properly dosed cannabis, potentially enhancing wheelchair propulsion and reducing secondary upper limb pain. However, patients must understand that cannabis can affect cognitive function and balance perception, requiring careful consideration before operating powered wheelchairs or attempting advanced manual wheelchair techniques.

Conclusion

Medical cannabis represents a potentially valuable option for SCI patients struggling with treatment-resistant spasticity and neuropathic pain. Whilst evidence from MS applications provides optimism, specialist assessment remains essential to ensure appropriateness and safety.

Medical Cannabis for Spinal Cord Injuries UK: Spasticity and Pain